| The pathogenesis of rheumatoid arthritis IB McInnes, G Schett New England Journal of Medicine 365 (23), 2205-2219, 2011 | 6325 | 2011 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 5737 | 2017 |
| Cytokines in the pathogenesis of rheumatoid arthritis IB McInnes, G Schett Nature Reviews Immunology 7 (6), 429-442, 2007 | 3119 | 2007 |
| Treating rheumatoid arthritis to target: recommendations of an international task force JS Smolen, D Aletaha, JWJ Bijlsma, FC Breedveld, D Boumpas, ... Annals of the rheumatic diseases 69 (4), 631-637, 2010 | 2901 | 2010 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2612 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs JS Smolen, R Landewé, FC Breedveld, M Dougados, P Emery, ... Annals of the rheumatic diseases 69 (6), 964-975, 2010 | 2384 | 2010 |
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis MJL Peters, DPM Symmons, D McCarey, BAC Dijkmans, P Nicola, ... Annals of the rheumatic diseases 69 (2), 325-331, 2010 | 1993 | 2010 |
| Guidelines for the use of flow cytometry and cell sorting in immunological studies A Cossarizza, HD Chang, A Radbruch, A Acs, D Adam, S Adam‐Klages, ... European journal of immunology 49 (10), 1457-1973, 2019 | 1729 | 2019 |
| COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options TJ Guzik, SA Mohiddin, A Dimarco, V Patel, K Savvatis, FM Marelli-Berg, ... Cardiovascular research 116 (10), 1666-1687, 2020 | 1623 | 2020 |
| Evidence that cytokines play a role in rheumatoid arthritis FM Brennan, IB McInnes The Journal of clinical investigation 118 (11), 3537-3545, 2008 | 1436 | 2008 |
| The JAK-STAT pathway: impact on human disease and therapeutic intervention JJ O'Shea, DM Schwartz, AV Villarino, M Gadina, IB McInnes, A Laurence Annual review of medicine 66, 311-328, 2015 | 1427 | 2015 |
| EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update R Agca, SC Heslinga, S Rollefstad, M Heslinga, IB McInnes, MJL Peters, ... Annals of the rheumatic diseases 76 (1), 17-28, 2017 | 1389 | 2017 |
| Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis N Sattar, DW McCarey, H Capell, IB McInnes Circulation 108 (24), 2957-2963, 2003 | 1386 | 2003 |
| Pathogenetic insights from the treatment of rheumatoid arthritis IB McInnes, G Schett The Lancet 389 (10086), 2328-2337, 2017 | 1217 | 2017 |
| Disease-associated functions of IL-33: the new kid in the IL-1 family FY Liew, NI Pitman, IB McInnes Nature Reviews Immunology 10 (2), 103-110, 2010 | 1210 | 2010 |
| European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update L Gossec, JS Smolen, S Ramiro, M De Wit, M Cutolo, M Dougados, ... Annals of the rheumatic diseases 75 (3), 499-510, 2016 | 1144 | 2016 |
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial DW McCarey, IB McInnes, R Madhok, R Hampson, O Scherbakova, I Ford, ... The Lancet 363 (9426), 2015-2021, 2004 | 1140 | 2004 |
| Immunopathogenesis of rheumatoid arthritis GS Firestein, IB McInnes Immunity 46 (2), 183-196, 2017 | 1123 | 2017 |
| Interleukin-18 JA Gracie, SE Robertson, IB McInnes Journal of Leucocyte Biology 73 (2), 213-224, 2003 | 1052 | 2003 |
| Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial IB McInnes, PJ Mease, B Kirkham, A Kavanaugh, CT Ritchlin, P Rahman, ... The Lancet 386 (9999), 1137-1146, 2015 | 1010 | 2015 |
